<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=7445162&amp;fmt=gif"> Skip to main content
Leukocare Register Now
viral-vector-beyond-frozen-storage-hero-3

Live webinar · 24 November 2026 · 10:00 AM ET

Melting the Future of Viral Vectors: Beyond Frozen Storage

Does your viral vector really need to stay frozen, or has frozen storage become the default too easily?

Dr. Cornelius Pompe, COO at Leukocare, leads a focused 45-minute discussion on viral vector stability, formulation and the development decisions that matter before moving beyond frozen storage.

45 min live Live Decision Case Live Q&A

What we’ll explore

Three questions that shape viral vector stability decisions

01

Does your vector truly need to stay frozen?

Understand which evidence can support or challenge frozen storage as the default.

02

What is really driving instability?

Explore how the vector, formulation and relevant stresses can interact.

03

What should you investigate first?

Prioritize decision-critical development work when material and time are limited.

After 45 minutes, you should have a clearer framework for deciding what matters now and what can wait.

Live Decision Case

A development decision. Limited information. What would you do next?

During the webinar, Cornelius will introduce a realistic viral-vector development scenario. You’ll decide what you would investigate next. Then we’ll unpack which information changes the decision, what to prioritize first and why.

Save your spot

  • A realistic development scenario

  • Which information actually changes the decision?

  • How the thinking applies to your own program

Webinar speaker

Meet your speaker

dr-cornelius-pompe-2

Dr. Cornelius Pompe

Chief Operating Officer (COO), Leukocare AG

Dr. Cornelius Pompe brings more than 20 years of experience across biotechnology and life sciences. Before joining Leukocare, he held leadership roles at biotechnology companies and pharmaceutical service organizations including Amgen, LFB and Coriolis. At Leukocare, he contributes extensive experience in drug product development, formulation, operational strategy and the development of complex biologics and advanced therapies.

Is this session for you?

This session is for you if…

The discussion is designed for teams making practical viral-vector stability and formulation decisions.

  • You are responsible for viral vector CMC or drug product development.
  • You have limited internal formulation expertise.
  • You are working with scarce vector material.
  • You face stability or frozen-storage questions for your current program.
  • You need to decide what development work is worth doing now versus later.

Questions before the webinar

Frequently asked questions

Practical questions about viral-vector stability, formulation development and storage strategy.

Do viral vectors always need frozen storage?

No. The appropriate storage format depends on the vector, formulation, required shelf life and intended use. We can evaluate frozen, refrigerated liquid or lyophilized options where suitable. Feasibility must be demonstrated for the specific vector.

How do you assess whether a viral vector formulation is stable?

We combine analytical methods that assess relevant physical and chemical attributes with suitable measures of biological activity. The methods are selected for the vector and study objective. Particle or genome measurements alone may not show whether biological function has been retained.

Can you assess losses during thawing, dilution and administration?

Yes. We can investigate relevant preparation and administration steps, including freeze–thaw exposure, dilution, holding times and contact with syringes, filters or infusion tubing. The results help identify losses in vector recovery or biological activity and support practical handling conditions.

Can you improve viral vector stability while preserving biological activity?

Yes. We investigate how formulation composition, storage and handling affect vector integrity and biological activity. Depending on the vector, relevant challenges include aggregation, adsorption to surfaces and loss of potency or infectivity. Formulation candidates are evaluated against the agreed product requirements.

Can you develop a formulation when vector material is limited?

Yes. We review existing data and prioritize the most important development questions before designing experiments. Studies can be structured into focused stages, with a material budget agreed in advance. The required amount depends on the vector, analytical methods and scope.

24 November 2026 · 10:00 AM ET

Save your spot

Register for a focused 45-minute discussion with Dr. Cornelius Pompe on viral vector stability, formulation and the development decisions behind storage strategy.

Live Decision Case · Live Q&A